Posted by Michael Wonder on 06 Oct 2021
Complete response letter received from FDA
6 October 2021 - Requirement to address approvability issues identified by FDA ahead of NDA resubmission
Polarean Imaging announces that the Company has received a complete response letter from the U.S. FDA for the new drug application for their drug-device combination product.
